ABSTRACT
Cigarette smoking is the number one avoidable killer in the industrial world. Yet doctors frequently do not treat or prevent the disease as they should. Education and training are lacking. In the present article an overview of these and other smoking-related problems and, at the same time, a description of the practical management of an outpatient clinic for smoking cessation, the epidemiology of smoking, the related risks and mortality, as well as the advantages of quitting are presented. The toxicology and pharmacology are discussed, in relation to addiction and craving. The article also includes the diagnosis of nicotine-dependence and nicotine replacement as well as bupropione and acupuncture treatments. The gain in body weight, depression and relapse are also dealt with. The various and personally tailored therapeutic strategies used in a service operating in a setting of Internal Medicine are presented and discussed.
Subject(s)
Smoking Cessation/methods , Smoking/therapy , Behavior Therapy , Humans , Smoking/adverse effects , Smoking/epidemiologyABSTRACT
We describe the prevalence of hepatitis C virus (HCV) infection among noninjection users of heroin in Italy and compare the prevalence of HCV infection among noninjection drug users (NIDUs) and injection drug users (IDUs). Multiple logistic regression analysis of data from NIDUs showed that hepatitis B virus (HBV) infection status was the only independent predictor of HCV seroprevalence. Among IDUs, the number of years of drug use and HBV and human immunodeficiency virus infection status were independent predictors of HCV seropositivity. We found an HCV infection prevalence of 20% among NIDUs. This rate was much lower than that for IDUs, who are 11 times more likely to have antibodies against HCV. The prevalence of HCV infection was much higher than that of HBV infection among the IDUs. In contrast, the prevalence of HBV infection was slightly higher than that of HCV infection among unvaccinated NIDUs. The prevalence of HCV infection among long-term IDUs approached true population saturation; among long-term NIDUs, however, it appeared to plateau at approximately 40%. Additional research on HCV infection among NIDUs is needed to develop a strategic prevention program for this patient subgroup.
